GRTX
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.02 | $0 | — |
| 2025 Q4 | 1.56 | $0 | -$2M |
| 2025 Q3 | -0.01 | $0 | -$757,000 |
| 2025 Q2 | -0.01 | $0 | $2M |
| 2025 Q1 | -0.03 | $0 | -$2M |
| 2024 Q4 | -0.09 | $0 | -$2M |
| 2024 Q3 | -0.10 | $0 | $8M |
| 2024 Q2 | -0.07 | $0 | -$3M |